Articles

This 401(k) lawsuit showcases the power of a 50-year-old law 

Erisa laid the foundation for retirement security, but more laws will bolster it in the years to come.

These stock-market watchers love this sector — and it’s not technology

My report on stocks and funds popular among top-performing investment newsletters

The bull market is entering its 3rd year. Here’s what history says will happen next.

U.S. stocks were kicking off their third year in the bull market with the S&P 500 touching a fresh record high on Monday afternoon — but history suggests investors need to be prepared for a potential setback in the coming 12 months. 

After Trump vs. Harris election, these bitcoin traders expect rally to $100,000

Bitcoin options traders expect limited volatility around the U.S. presidential election on Nov. 5, but anticipate a year-end rally that could carry the crypto as high as $100,000.

How to make money on stocks that look ripe for 2024 tax-loss selling

These 20 stocks are being unfairly punished. They’ll likely bounce back in January.

I’m planning to loan my son money to build a house — he was priced out of the housing market. What could go wrong?

”I haven’t heard of anyone doing this, so I’m not sure it’s even legal.”

Junk-rated companies face record refinancing needs above $2 trillion through 2029, Moody’s says

Barring an economic slowdown, market conditions are still favorable, with interest rates expected to continue to come down and investors expected to be receptive to credit markets

Southwest’s stock falls after activist calls special meeting to elect new board

Southwest Airlines’ stock took a turn lower Monday, after activist investor Elliott Investment Management called for a special meeting to give shareholders a chance to elect “a completely independent” board of directors.

Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

Why Apple’s stock is a sweet play ahead of earnings, according to this analyst

An Evercore ISI analyst thinks Apple looks primed to capitalize on low investor expectations for the latest quarter.

Amgen’s stock falls as analyst warns that hype around obesity drug is baked in

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

Nvidia’s stock heads for first record high in months as customers seem locked in

One analyst says customers are in a “prisoner’s dilemma” that will keep them spending, while another was encouraged by recent Nvidia commentary on the company’s “moat.”
1 816 817 818 819 820 2,430